Kim Woo Ju, Kim Han Koo
Department of Plastic and Reconstructive Surgery, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University School of Medicine, Gwangmyeong, Korea.
Department of Plastic and Reconstructive Surgery, Chung-Ang University Hospital, Chung-Ang University School of Medicine, Seoul, Korea.
Arch Craniofac Surg. 2023 Oct;24(5):203-210. doi: 10.7181/acfs.2023.00409. Epub 2023 Oct 20.
Angiosarcoma is a very rare soft tissue sarcoma that originates from endothelial cells and typically has a poor prognosis. It is most commonly found in elderly white men and can occur anywhere in the body, particularly in the head, neck, and scalp. Patients who have undergone previous radiation treatment or who have chronic lymphedema also face an elevated risk of this condition. Various genetic changes are suspected to contribute to the development of angiosarcoma, and these changes have been identified as potential targets for treatment. For localized disease, wide surgical resection is often the prudent course of action. A multidisciplinary approach, which may include surgery, radiotherapy, systemic chemotherapy, or immunotherapy, is typically the most effective way to achieve favorable outcomes. In this review, we discuss the general understanding of angiosarcoma and its management, with a particular focus on the current evolving treatments for the disease.
血管肉瘤是一种非常罕见的软组织肉瘤，起源于内皮细胞，通常预后较差。它最常见于老年白人男性，可发生于身体的任何部位，尤其是头部、颈部和头皮。既往接受过放射治疗或患有慢性淋巴水肿的患者也面临着患这种疾病的风险升高。各种基因变化被怀疑与血管肉瘤的发生有关，并且这些变化已被确定为潜在的治疗靶点。对于局限性疾病，广泛的手术切除通常是谨慎的行动方案。多学科方法，可能包括手术、放疗、全身化疗或免疫治疗，通常是取得良好结果的最有效方法。在本综述中，我们讨论了对血管肉瘤及其管理的一般认识，特别关注该疾病当前不断发展的治疗方法。
